Benitec Biopharma (BNTC) Competitors

Benitec Biopharma (NASDAQ:BNTC) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.

Which has better earnings & valuation, BNTC or ETNB?

Benitec Biopharma has higher revenue and earnings than 89bio. Benitec Biopharma is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	$80K	4,106.86	-$21.75M	-$1.51	-9.28
89bio	N/A	N/A	-$142.19M	-$3.43	-2.34

Does the media prefer BNTC or ETNB?

In the previous week, Benitec Biopharma had 5 more articles in the media than 89bio. MarketBeat recorded 11 mentions for Benitec Biopharma and 6 mentions for 89bio. Benitec Biopharma's average media sentiment score of 0.70 beat 89bio's score of 0.52 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
89bio	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, BNTC or ETNB?

Benitec Biopharma has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, 89bio has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.

Is BNTC or ETNB more profitable?

Benitec Biopharma's return on equity of -44.61% beat 89bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-44.61%	-41.25%
89bio	N/A	-59.58%	-52.21%

Do institutionals and insiders believe in BNTC or ETNB?

52.2% of Benitec Biopharma shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by company insiders. Comparatively, 2.8% of 89bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community favor BNTC or ETNB?

Benitec Biopharma received 82 more outperform votes than 89bio when rated by MarketBeat users. Likewise, 65.55% of users gave Benitec Biopharma an outperform vote while only 63.33% of users gave 89bio an outperform vote.

Company	Underperform	Outperform
Benitec Biopharma	Outperform Votes 196 65.55%	Underperform Votes 103 34.45%
89bio	Outperform Votes 114 63.33%	Underperform Votes 66 36.67%

Do analysts rate BNTC or ETNB?

Benitec Biopharma currently has a consensus target price of $24.43, indicating a potential upside of 74.37%. 89bio has a consensus target price of $27.56, indicating a potential upside of 243.59%. Given 89bio's higher probable upside, analysts clearly believe 89bio is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22
89bio	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Benitec Biopharma beats 89bio on 12 of the 16 factors compared between the two stocks.